With respect to the OS analysis, we were unable to test more variables with possible prognostic value because they were inconsistently available in the patients’ medical records, such as biochemical markers (e.g., calcium and alkaline phosphatase levels, albumin levels, leucocyte count), previous systemic therapies (many patients were previously treated in other facilities and had incomplete documentation), molecular subtype for breast and lung cancers, comorbidities. This evidence concerns the gene ALB and lung cancer.